Key result
Doxazosin-ER-GITS provides stable BP control with fewer side effects as adjunctive therapy for resistant hypertension.
Why the study?
Blood pressure control rates remain suboptimal despite advances in antihypertensive therapy, with barriers including cost, side effects, therapeutic complexity, and physician inertia impeding effective management.
Does doxazosin ER-GITS improve blood pressure control and tolerability compared to immediate-release formulations in patients with hypertension?
Does doxazosin ER-GITS improve blood pressure control and tolerability compared to immediate-release formulations in patients with hypertension?
Doxazosin ER-GITS offers a better tolerability profile than immediate-release doxazosin, making it a useful add-on therapy for resistant hypertension, particularly when spironolactone is contraindicated or poorly tolerated.
Hypertension remains a leading global cause of cardiovascular morbidity and mortality, yet blood pressure control rates remain suboptimal despite advances in antihypertensive therapy. Multiple barriers-including cost, side effects, therapeutic complexity, and physician inertia-impede effective management, particularly in aging populations and low-resource settings. This review evaluates the therapeutic role of doxazosin, particularly in its extended-release gastrointestinal therapeutic system formulation, as a potential adjunct in contemporary hypertension treatment, including resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Camafort et al. (2025) conducted a review in Hypertension and Resistant Hypertension. Doxazosin GITS (extended release) was evaluated. Doxazosin-ER-GITS provides stable blood pressure control with fewer side effects and serves as a valuable adjunctive therapy for patients with resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: